vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and TRANSACT TECHNOLOGIES INC (TACT). Click either name above to swap in a different company.
TRANSACT TECHNOLOGIES INC is the larger business by last-quarter revenue ($11.5M vs $10.7M, roughly 1.1× Arbutus Biopharma Corp). On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs 11.9%). Over the past eight quarters, TRANSACT TECHNOLOGIES INC's revenue compounded faster (3.5% CAGR vs -13.2%).
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
Roper Technologies, Inc. is a holding company that owns companies in the technology sector.
ABUS vs TACT — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $11.5M |
| Net Profit | $2.5M | — |
| Gross Margin | — | 47.6% |
| Operating Margin | 13.9% | -10.1% |
| Net Margin | 23.5% | — |
| Revenue YoY | 522.2% | 11.9% |
| Net Profit YoY | 112.7% | — |
| EPS (diluted) | $0.01 | $-0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $11.5M | ||
| Q3 25 | — | $13.2M | ||
| Q2 25 | $10.7M | $13.8M | ||
| Q1 25 | — | $13.1M | ||
| Q4 24 | — | $10.2M | ||
| Q3 24 | — | $10.9M | ||
| Q2 24 | — | $11.6M | ||
| Q1 24 | — | $10.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | $15.0K | ||
| Q2 25 | $2.5M | $-143.0K | ||
| Q1 25 | — | $19.0K | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-551.0K | ||
| Q2 24 | — | $-319.0K | ||
| Q1 24 | — | $-1.0M |
| Q4 25 | — | 47.6% | ||
| Q3 25 | — | 49.8% | ||
| Q2 25 | — | 48.2% | ||
| Q1 25 | — | 48.7% | ||
| Q4 24 | — | 44.2% | ||
| Q3 24 | — | 48.1% | ||
| Q2 24 | — | 52.7% | ||
| Q1 24 | — | 52.6% |
| Q4 25 | — | -10.1% | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | 13.9% | -1.9% | ||
| Q1 25 | — | -0.1% | ||
| Q4 24 | — | -10.3% | ||
| Q3 24 | — | -7.7% | ||
| Q2 24 | — | -3.8% | ||
| Q1 24 | — | -12.2% |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | 23.5% | -1.0% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -5.1% | ||
| Q2 24 | — | -2.8% | ||
| Q1 24 | — | -9.7% |
| Q4 25 | — | $-0.11 | ||
| Q3 25 | — | $0.00 | ||
| Q2 25 | $0.01 | $-0.01 | ||
| Q1 25 | — | $0.00 | ||
| Q4 24 | — | $-0.80 | ||
| Q3 24 | — | $-0.06 | ||
| Q2 24 | — | $-0.03 | ||
| Q1 24 | — | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $20.4M |
| Total DebtLower is stronger | $0 | — |
| Stockholders' EquityBook value | $83.0M | $31.1M |
| Total Assets | $103.3M | $44.8M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $20.4M | ||
| Q3 25 | — | $20.0M | ||
| Q2 25 | $37.4M | $17.7M | ||
| Q1 25 | — | $14.2M | ||
| Q4 24 | — | $14.4M | ||
| Q3 24 | — | $11.3M | ||
| Q2 24 | — | $11.1M | ||
| Q1 24 | — | $10.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $0 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $31.1M | ||
| Q3 25 | — | $31.8M | ||
| Q2 25 | $83.0M | $31.3M | ||
| Q1 25 | — | $30.9M | ||
| Q4 24 | — | $30.6M | ||
| Q3 24 | — | $38.4M | ||
| Q2 24 | — | $38.5M | ||
| Q1 24 | — | $38.6M |
| Q4 25 | — | $44.8M | ||
| Q3 25 | — | $45.0M | ||
| Q2 25 | $103.3M | $44.5M | ||
| Q1 25 | — | $44.2M | ||
| Q4 24 | — | $44.0M | ||
| Q3 24 | — | $50.5M | ||
| Q2 24 | — | $50.4M | ||
| Q1 24 | — | $51.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $609.0K |
| Free Cash FlowOCF − Capex | — | $589.0K |
| FCF MarginFCF / Revenue | — | 5.1% |
| Capex IntensityCapex / Revenue | 0.0% | 0.2% |
| Cash ConversionOCF / Net Profit | -6.24× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $7.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $609.0K | ||
| Q3 25 | — | $3.6M | ||
| Q2 25 | $-15.7M | $3.6M | ||
| Q1 25 | — | $-161.0K | ||
| Q4 24 | — | $2.4M | ||
| Q3 24 | — | $327.0K | ||
| Q2 24 | — | $636.0K | ||
| Q1 24 | — | $-1.5M |
| Q4 25 | — | $589.0K | ||
| Q3 25 | — | $3.6M | ||
| Q2 25 | — | $3.6M | ||
| Q1 25 | — | $-171.0K | ||
| Q4 24 | — | $2.4M | ||
| Q3 24 | — | $259.0K | ||
| Q2 24 | — | $499.0K | ||
| Q1 24 | — | $-1.6M |
| Q4 25 | — | 5.1% | ||
| Q3 25 | — | 27.1% | ||
| Q2 25 | — | 25.9% | ||
| Q1 25 | — | -1.3% | ||
| Q4 24 | — | 23.2% | ||
| Q3 24 | — | 2.4% | ||
| Q2 24 | — | 4.3% | ||
| Q1 24 | — | -14.9% |
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | 0.5% | ||
| Q2 25 | 0.0% | 0.1% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 0.6% | ||
| Q2 24 | — | 1.2% | ||
| Q1 24 | — | 1.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 242.00× | ||
| Q2 25 | -6.24× | — | ||
| Q1 25 | — | -8.47× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
